We have recruited a talent and outstanding team, including R & D, clinical research, management and technical consultant departments, delivering excellent teamwork for new drug development and company star up. To reduce withdrawal symptoms of opiate substance, opium dependence and the chance of abuse, we designed the suitable development plans and clinical trials. In order to respond promptly to domestic and foreign laws, regulations, and policy changes, we have also planned the launch schedule of products and management strategies. Our senior industrial, academic and research professional consultants will operate the new company to effectively mitigate the satiation of global opium addiction, and subsequently ease the medical burden and social crime chaos.
Currently, the international pharmaceutical companies have had a lot of drugs for treatments of popular diseases. It is difficult to develop new drugs to compete with existing drugs. Therefore, our team focuses on the unmet medical need-“clinical care of opium addiction”. We identified a new molecular target involving in opium addiction. We had screened out a lot of existing drugs and further synthesized new chemical drugs for studies on the target. The results of animal trials have proven that some drugs are effective to prevent and cure opium addiction. The drugs have been applied to patent protection for new indications and human clinical trials have further carried out. Drug repurposing significantly shorten the development time and cut down risk. New compound drug, applying to 505 (b)(1) regulations for new drug application, have a longer patent protection, market exclusivity and high rate of return. Therefore, we will use these strategies to effectively reduce the probability of failure and accelerate the processes of drug development. It is also can increase economic value, ease medical costs and solve social problems.
According to the United Nations Office on Drugs and Crime (UNODC) in 2015, opium abusers accounted for 1.1% of the global adult population (equivalent to about 50 million people) and continued to rise. Besides, according to GlobalData data, the net present value (NPV) of opium addiction is about $ 3.2 billion per year. In addition, another part of the market for the addiction is the pain treatment by opioid medication. The data of the IMS Health (Universal Technology Data Management Co., Ltd.) showed that medical cost of opium painkillers expenses up to $ 1.4 million in the US market in 2014. In view of this, we will use undifferentiated marketing strategy to market our products. Because our products are novel and exclusive on treatment of opiate addiction, after NDA, our products will subvert and replace the existing treatment of opiate addiction.